{"id":10362,"date":"2021-07-07T18:50:34","date_gmt":"2021-07-07T16:50:34","guid":{"rendered":"https:\/\/www.nicox.com\/pipeline-markets-and-science\/"},"modified":"2025-09-04T08:26:05","modified_gmt":"2025-09-04T06:26:05","slug":"pipeline-markets-and-science","status":"publish","type":"page","link":"https:\/\/www.nicox.com\/fr\/pipeline-markets-and-science\/","title":{"rendered":"Pipeline, Markets and Science"},"content":{"rendered":"\n<div class=\"c-page-title c-wrapper\">\n\n    <div class=\"[ c-container ] [ u-align-center ]\" data-variant=\"narrow-column\">\n    \n        <h1 class=\"[ c-page-title__text ] [ u-text-base sm:u-text-plus-1 u-weight-bold ] [  ]\">\n\n            Pipeline, Markets and Science\n            \n        <\/h1>\n\n        <hr class=\"[ c-page-title__hr ] [ u-color-blue-4 ]\">\n    \n    <\/div>\n\n<\/div>\n\n\n\n\n<section class=\"[ c-wrapper c-offset-stats ] [  u-bg-blue-1 ]\">\n\n    <div class=\"c-block-anchor\" id=\"ophthalmology-market\"><\/div>\n\n    <div class=\"c-container\" data-variant=\"wide-column\">\n\n        <div class=\"[ c-offset-stats__title-group ] [ u-gap-top-plus-3 ]\">\n\n            \n                <h2 class=\"[ c-offset-stats__title ] [ u-text-plus-1 lg:u-text-plus-2 u-weight-bold ]\">\n                    Ophthalmology market:\n                <\/h2>\n\n            \n            \n                <span class=\"[ c-offset-stats__subtitle ] [ u-text-plus-1 lg:u-text-plus-2 u-weight-light ]\">\n                    Glaucoma and Allergic Conjunctivitis\n                <\/span>\n\n            \n        <\/div>\n\n    <\/div>\n\n    <div class=\"c-container\">\n\n        <div class=\"[ c-offset-stats__grid ]\">\n\n            \n                <article class=\"[ c-offset-stats__block ]\" data-slide-in>\n\n                                        \n                        <span class=\"[ c-offset-stats__block-stat ] [ u-text-plus-4 u-weight-light ]\" style=\"color: #88a9aa;\">\n                            $6.0bn\n                        <\/span>\n                    \n                                    \n                                            <h3 class=\"[ c-offset-stats__block-title ] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            Worldwide sales \n                        <\/h3>\n                                    \n                    \n                        <div class=\"[ c-offset-stats__block-content ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            Worldwide sales of treatments targeting glaucoma were over $6.0 billion, out of a $24.3 billion worldwide market for ophthalmic drugs in 2020. (data from IQVIA Analytics Link 2020) .\n                        <\/div>\n\n                    \n                <\/article>\n\n            \n                <article class=\"[ c-offset-stats__block ]\" data-slide-in>\n\n                                        \n                        <span class=\"[ c-offset-stats__block-stat ] [ u-text-plus-4 u-weight-light ]\" style=\"color: ;\">\n                            $3.0bn\n                        <\/span>\n                    \n                                    \n                                            <h3 class=\"[ c-offset-stats__block-title ] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            Glaucoma treatments\n                        <\/h3>\n                                    \n                    \n                        <div class=\"[ c-offset-stats__block-content ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            In the U.S., sales of treatments targeting glaucoma totaled $3.0 billion in 2020 or 27% of the $11.1 billion U.S. market for ophthalmic drugs (data from IQVIA Analytics Link 2020).\n                        <\/div>\n\n                    \n                <\/article>\n\n            \n                <article class=\"[ c-offset-stats__block ]\" data-slide-in>\n\n                                        \n                        <span class=\"[ c-offset-stats__block-stat ] [ u-text-plus-4 u-weight-light ]\" style=\"color: #0a4d9e;\">\n                            $360m\n                        <\/span>\n                    \n                                    \n                                            <h3 class=\"[ c-offset-stats__block-title ] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            Allergic conjunctivitis market\n                        <\/h3>\n                                    \n                    \n                        <div class=\"[ c-offset-stats__block-content ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            The annual U.S market for topical prescription treatments of allergic conjunctivitis totals approximately $360 million (data from Analytics Link 2020) \n                        <\/div>\n\n                    \n                <\/article>\n\n            \n        <\/div>\n\n    <\/div>\n\n<\/section>\n\n\n<section class=\"[ c-portfolio c-wrapper ] [  ]\">\n\n    <div class=\"c-block-anchor\" id=\"portfolio\"><\/div>\n\n    <div class=\"c-container\">\n\n        \n            <h2 class=\"[ c-portfolio__title ] [ u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                Our portfolio at a glance\n            <\/h2>\n\n        \n        \n    <\/div>\n\n    \n        <div class=\"c-portfolio__container\">\n    \n            \n                <h3 class=\"[ c-portfolio__section-heading ] [ u-gap-top-plus-3 u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\" style=\"color: #b7b494;\">\n                    NO-donating products and product candidates targeting glaucoma\n                <\/h3>\n            \n            \n        <\/div>\n\n        <div class=\"c-portfolio__grid-container\">\n\n            <div class=\"c-portfolio__grid\">\n\n                                \n                \n                    <article class=\"c-product\">\n\n                        <div class=\"c-block-anchor\" id=\"product-ncx-470\"><\/div>\n\n                        <hr>\n                    \n                        <h4 class=\"[ c-product__title] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            NCX 470\n                        <\/h4>\n                        \n                        <h5 class=\"[ c-product__type ] [ u-gap-top-plus-2 u-text-minus-2 u-weight-bold ]\">\n                            Principal candidat m\u00e9dicament en d\u00e9veloppement clinique de Nicox\n                        <\/h5>\n                        \n                        <div class=\"[ c-product__excerpt ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            NCX 470 est un nouveau collyre bimatoprost donneur d\u2019oxyde nitrique (NO), en d\u00e9veloppement clinique pour la r\u00e9duction de la pression intraoculaire (PIO) chez des patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire. Deux essais cliniques de Phase 3 ont \u00e9t\u00e9 achev\u00e9s avec succ\u00e8s et des demandes d\u2019autorisation de mise sur le march\u00e9 sont en cours de pr\u00e9paration aux \u00c9tats-Unis et en Chine, tandis qu\u2019un programme distinct de Phase 3 est en cours au Japon.\n                        <\/div>\n                        \n                        <button class=\"[ c-icon-link c-product__readmore ] [ u-gap-top-threequarter u-text-minus-2 ]\" data-disclosure-toggle=\"ncx-470\" data-open-details data-variant=\"medium\">\n                            <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                            <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                            <\/span>\n                        \n                        <\/button>\n\n                        <div class=\"[ c-wrapper c-detail c-portfolio__detail ]\" data-disclosure-target=\"ncx-470\">\n\n                            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"ncx-470\" data-close-details><\/button>\n\n                                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"ncx-470\" data-close-details data-variant=\"medium\">\n\n                                        <span class=\"c-icon-link__text\">\n                                            Fermer\n                                        <\/span>\n\n                                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                                        <\/span>\n\n                                    <\/button>\n\n                                    \n                                        <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold u-leading-loose ]\">\n                                            NCX 470<br>\n                                        \n                                                                                            <div class=\"u-gap-top-quarter u-color-grey-2 u-text-minus-1 sm:u-text-base u-weight-light u-leading-base\">\n                                                    <span class=\"u-color-white\" aria-hidden=\"true\"> Statut :<\/span> \n                                                    <p><strong>Etude de phase 3 Mont Blanc et Denali achev\u00e9es &#8211;<\/strong><strong>Etude de phase 3b Whistler achev\u00e9e<\/strong><\/p>\n<p><strong>Contrat de licence exclusif avec Kowa pour le d\u00e9veloppement et la commercialisation du NCX 470 dans l&rsquo;ensemble des territoires du monde en dehors de la Chine, de la Cor\u00e9e et de l&rsquo;Asie du Sud-Est o\u00f9 NCX 470 est licenci\u00e9 \u00e0 Ocumension.<\/strong><\/p>\n<p><strong>Etudes cliniques de Phase 3 en cours au Japon.<\/strong><\/p>\n\n                                                <\/div>\n                                                                                    <\/h2>\n\n                                    \n                                <\/header>\n\n                                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                                                                        \n                                        <h3 class=\"[ c-portfolio__milestone-title ] [ u-gap-top-minus-2 sm:u-gap-top-base u-text-minus-2 u-weight-bold ]\">\n                                            Etapes attendues : \n                                        <\/h3>\n\n                                    \n                                                                        \n                                        <ul>\n                                                                                            <li>Demandes d&rsquo;autorisation de mise sur le march\u00e9 en cours de pr\u00e9paration aux \u00c9tats-Unis et en Chine <\/li>\n                                                                                    <\/ul>\n\n                                    \n                                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                                    <div class=\"u-color-grey-2\">\n\n                                        <p>NCX 470 est un nouveau collyre bimatoprost donneur d\u2019oxyde nitrique (NO) qui utilise les puissants effets de r\u00e9duction de la pression intraoculaire (PIO) de l\u2019oxyde nitrique (NO) et des analogues de prostaglandine (PGAs). NCX 470 conjugue la plateforme de recherche de Nicox de compos\u00e9s donneurs de NO et le bimatoprost dans une seule mol\u00e9cule. NCX 470 est con\u00e7u pour lib\u00e9rer du bimatoprost et du NO dans l\u2019\u0153il afin de r\u00e9duire la PIO par le biais de deux voies de drainage chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire. Le NO est une petite mol\u00e9cule messager naturelle, bien connue, qui joue un r\u00f4le cl\u00e9 dans la r\u00e9gulation de la PIO au travers de l\u2019activation de la Guanylate Cyclase soluble (GCs). L\u2019oxyde nitrique apporte une efficacit\u00e9 de r\u00e9duction de la PIO suppl\u00e9mentaire en am\u00e9liorant le drainage de l\u2019humeur aqueuse de l\u2019\u0153il via un m\u00e9canisme d\u2019action diff\u00e9rent de celui des analogues de prostaglandine. Le bimatoprost, commercialis\u00e9 sous le nom de sp\u00e9cialit\u00e9 Lumigan\u00ae par AbbVie, Inc., est le principal produit de sp\u00e9cialit\u00e9 de la classe des analogues de prostaglandine. Les analogues de prostaglandine sont la classe des m\u00e9dicaments la plus couramment utilis\u00e9e pour la r\u00e9duction de la PIO chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire.<\/p>\n<p>NCX 470 a achev\u00e9 deux essais cliniques de Phase 3 con\u00e7us pour r\u00e9pondre aux exigences r\u00e9glementaires en mati\u00e8re de s\u00e9curit\u00e9 et d\u2019efficacit\u00e9, en vue de soutenir les demandes d\u2019Autorisation de Mise sur le March\u00e9 (NDA) aux \u00c9tats-Unis et en Chine, <a href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/FR-_NCX-470-MontBlanc-Phase-3-Topline-results-PR_V20221031_F.pdf\">Mont Blanc<\/a> et <a href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/FR_NCX470DenaliToplineAugust2025_PR_FINAL.pdf\">Denali<\/a>. Les deux essais ont donn\u00e9 des r\u00e9sultats positifs et atteint les crit\u00e8res d\u2019efficacit\u00e9 requis pour le d\u00e9p\u00f4t d\u2019une demande d\u2019autorisation de mise sur le march\u00e9 aux \u00c9tats-Unis et en Chine.<\/p>\n<p>NCX 470 a \u00e9galement fait l\u2019objet d\u2019une \u00e9tude de Phase 2, <a href=\"https:\/\/journals.lww.com\/glaucomajournal\/fulltext\/2022\/06000\/a_randomized,_controlled_comparison_of_ncx_470.3.aspx\">Dolomites<\/a>, ainsi que dans un essai de Phase 3b, <a href=\"https:\/\/www.nicox.com\/fr\/actualites-et-evenements\/communiques-de-presse\/#:~:text=Nicox%20annonce%20les%20r%C3%A9sultats%20de%20l%E2%80%99%C3%A9tude%20exploratoire%20de%20phase%203b%20Whistler%20dans%20le%20glaucome\">Whistler<\/a>, et un programme distinct de Phase 3 est en cours au Japon<\/p>\n<p>Des \u00e9tudes non cliniques exploratoires dans un mod\u00e8le bien d\u00e9fini de l\u00e9sions de la t\u00eate du nerf optique et de la r\u00e9tine (isch\u00e9mie\/reperfusion induites par l&rsquo;ET-1) ont \u00e9tudi\u00e9 les effets du NCX 470 au-del\u00e0 de ses propri\u00e9t\u00e9s de r\u00e9duction de la PIO. Les r\u00e9sultats sugg\u00e8rent que le NCX 470 am\u00e9liore la perfusion oculaire et la fonction r\u00e9tinienne dans les yeux endommag\u00e9s par rapport au v\u00e9hicule et au Lumigan<sup>\u00ae <\/sup>et pourrait donc avoir des propri\u00e9t\u00e9s protectrices pour la r\u00e9tine. <strong>\u00a0<\/strong>Les effets b\u00e9n\u00e9fiques de NCX 470 ont \u00e9galement \u00e9t\u00e9 d\u00e9montr\u00e9s dans un mod\u00e8le in vivo de l\u00e9sion des cellules r\u00e9tiniennes (voir <a href=\"https:\/\/www.nicox.com\/fr\/actualites-et-evenements\/communiques-de-presse\/#:~:text=Nicox%20%3A%20Protection%20des%20cellules%20r%C3%A9tiniennes%20par%20le%20NCX%20470%20montr%C3%A9e%20dans%20un%20mod%C3%A8le%20non%20clinique\">communiqu\u00e9 de presse du 29 septembre 2021<\/a>).<\/p>\n<p>NCX 470 est prot\u00e9g\u00e9 au niveau mondial par des brevets couvrant la composition de mati\u00e8re jusqu\u2019en 2029, avec une potentielle extension de la dur\u00e9e de la protection pouvant atteindre 5 ans aux Etats-Unis et en Europe, et par des brevets portant sur la formulation jusqu\u2019en 2039 aux Etats-Unis, en Europe, au Japon et en Chine et dans d\u2019autres territoires.<\/p>\n\n\n                                    <\/div>\n\n                                <\/div>\n\n                            <\/div>\n\n                        <\/div>\n                        \n                    <\/article>\n                    \n                \n            <\/div>\n\n        <\/div>\n    \n    \n        <div class=\"c-portfolio__container\">\n    \n            \n                <h3 class=\"[ c-portfolio__section-heading ] [ u-gap-top-plus-3 u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\" style=\"color: #88a9aa;\">\n                    Novel treatment to address unmet medical need in blepharitis\n                <\/h3>\n            \n            \n        <\/div>\n\n        <div class=\"c-portfolio__grid-container\">\n\n            <div class=\"c-portfolio__grid\">\n\n                                \n                \n            <\/div>\n\n        <\/div>\n    \n    \n        <div class=\"c-portfolio__container\">\n    \n            \n                <h3 class=\"[ c-portfolio__section-heading ] [ u-gap-top-plus-3 u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\" style=\"color: ;\">\n                    Out-licensed commercial products\n                <\/h3>\n            \n            \n        <\/div>\n\n        <div class=\"c-portfolio__grid-container\">\n\n            <div class=\"c-portfolio__grid\">\n\n                                \n                \n                    <article class=\"c-product\">\n\n                        <div class=\"c-block-anchor\" id=\"product-vyzulta\"><\/div>\n\n                        <hr>\n                    \n                        <h4 class=\"[ c-product__title] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            VYZULTA<sup>\u00ae<\/sup>\n                        <\/h4>\n                        \n                        <h5 class=\"[ c-product__type ] [ u-gap-top-plus-2 u-text-minus-2 u-weight-bold ]\">\n                            Un analogue de prostaglandine, dont l\u2019un des m\u00e9tabolites est l\u2019oxyde nitrique (NO)\n                        <\/h5>\n                        \n                        <div class=\"[ c-product__excerpt ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            VYZULTA<sup>\u00ae<\/sup> (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%, indiqu\u00e9 pour la r\u00e9duction de la pression intraoculaire (PIO) chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire,\r\n\r\nFait l\u2019objet d\u2019un accord de concession de licence exclusif mondial avec Bausch + Lomb, un leader mondial de la sant\u00e9 oculaire. VYZULTA est commercialis\u00e9 plus de 15 pays, dont les \u00c9tats-Unis, et est \u00e9galement approuv\u00e9 dans un certain nombre d&rsquo;autres pays. \r\n\r\n\r\n    Nicox a vendu les redevances de VYZULTA \u00e0 Soleus Capital en octobre 2024.\n                        <\/div>\n                        \n                        <button class=\"[ c-icon-link c-product__readmore ] [ u-gap-top-threequarter u-text-minus-2 ]\" data-disclosure-toggle=\"vyzulta\" data-open-details data-variant=\"medium\">\n                            <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                            <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                            <\/span>\n                        \n                        <\/button>\n\n                        <div class=\"[ c-wrapper c-detail c-portfolio__detail ]\" data-disclosure-target=\"vyzulta\">\n\n                            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"vyzulta\" data-close-details><\/button>\n\n                                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"vyzulta\" data-close-details data-variant=\"medium\">\n\n                                        <span class=\"c-icon-link__text\">\n                                            Fermer\n                                        <\/span>\n\n                                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                                        <\/span>\n\n                                    <\/button>\n\n                                    \n                                        <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold u-leading-loose ]\">\n                                            VYZULTA<sup>\u00ae<\/sup><br>\n                                        \n                                                                                            <div class=\"u-gap-top-quarter u-color-grey-2 u-text-minus-1 sm:u-text-base u-weight-light u-leading-base\">\n                                                    <span class=\"u-color-white\" aria-hidden=\"true\"> Statut :<\/span> \n                                                    <p>Mis sur le march\u00e9 dans plus de 15 pays, dont les \u00c9tats-Unis.<\/p>\n\n                                                <\/div>\n                                                                                    <\/h2>\n\n                                    \n                                <\/header>\n\n                                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                                                                        \n                                        <h3 class=\"[ c-portfolio__milestone-title ] [ u-gap-top-minus-2 sm:u-gap-top-base u-text-minus-2 u-weight-bold ]\">\n                                            Etapes attendues : \n                                        <\/h3>\n\n                                    \n                                                                        \n                                        <ul>\n                                                                                            <li>Revenus r\u00e9currents<\/li>\n                                                                                    <\/ul>\n\n                                    \n                                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                                    <div class=\"u-color-grey-2\">\n\n                                        <p>VYZULTA, dont les droits mondiaux exclusifs ont \u00e9t\u00e9 accord\u00e9s \u00e0 Bausch + Lomb, est un analogue de prostaglandine, dont l\u2019un des m\u00e9tabolites est l\u2019oxyde nitrique (NO). VYZULTA est indiqu\u00e9 aux Etats-Unis pour la r\u00e9duction de la PIO chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire. Lors de son approbation, VYZULTA \u00e9tait le premier collyre approuv\u00e9 au cours des 20 derni\u00e8res ann\u00e9es avec une nouvelle approche pour la r\u00e9duction de la PIO.<\/p>\n<p>VYZULTA a \u00e9t\u00e9 mis sur le march\u00e9 dans plus de 15 pays, dont les \u00c9tats-Unis, o\u00f9 il est prot\u00e9g\u00e9 par un brevet couvrant sa composition de mati\u00e8re jusqu\u2019en 2029.<\/p>\n<p>Nicox a vendu les redevances de VYZULTA \u00e0 Soleus Capital en octobre 2024.<\/p>\n<p>Plus d&rsquo;informations sur VYZULTA sur le site de notre partenaire\u00a0<a href=\"http:\/\/www.vyzulta.com\">http:\/\/www.vyzulta.com<\/a>\u00a0.<\/p>\n\n\n                                    <\/div>\n\n                                <\/div>\n\n                            <\/div>\n\n                        <\/div>\n                        \n                    <\/article>\n                    \n                \n                    <article class=\"c-product\">\n\n                        <div class=\"c-block-anchor\" id=\"product-zerviate\"><\/div>\n\n                        <hr>\n                    \n                        <h4 class=\"[ c-product__title] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            ZERVIATE<sup>\u00ae<\/sup>\n                        <\/h4>\n                        \n                        <h5 class=\"[ c-product__type ] [ u-gap-top-plus-2 u-text-minus-2 u-weight-bold ]\">\n                            Indiqu\u00e9 pour le traitement du prurit oculaire associ\u00e9 aux conjonctivites allergiques\n                        <\/h5>\n                        \n                        <div class=\"[ c-product__excerpt ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            ZERVIATE\u00ae (solution ophtalmique de c\u00e9tirizine) 0,24%, indiqu\u00e9 pour le traitement du prurit oculaire associ\u00e9 aux conjonctivites allergiques, est commercialis\u00e9 aux Etats-Unis par le partenaire am\u00e9ricain Harrow et en Chine par Ocumension Therapeutics. Un accord de concession de licence exclusif a \u00e9t\u00e9 conclu avec Ocumension Therapeutics pour le d\u00e9veloppement et la commercialisation de ZERVIATE sur le march\u00e9 chinois et la majorit\u00e9 des march\u00e9s d\u2019Asie du Sud-Est. \n                        <\/div>\n                        \n                        <button class=\"[ c-icon-link c-product__readmore ] [ u-gap-top-threequarter u-text-minus-2 ]\" data-disclosure-toggle=\"zerviate\" data-open-details data-variant=\"medium\">\n                            <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                            <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                            <\/span>\n                        \n                        <\/button>\n\n                        <div class=\"[ c-wrapper c-detail c-portfolio__detail ]\" data-disclosure-target=\"zerviate\">\n\n                            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"zerviate\" data-close-details><\/button>\n\n                                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"zerviate\" data-close-details data-variant=\"medium\">\n\n                                        <span class=\"c-icon-link__text\">\n                                            Fermer\n                                        <\/span>\n\n                                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                                        <\/span>\n\n                                    <\/button>\n\n                                    \n                                        <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold u-leading-loose ]\">\n                                            ZERVIATE<sup>\u00ae<\/sup><br>\n                                        \n                                                                                            <div class=\"u-gap-top-quarter u-color-grey-2 u-text-minus-1 sm:u-text-base u-weight-light u-leading-base\">\n                                                    <span class=\"u-color-white\" aria-hidden=\"true\"> Statut :<\/span> \n                                                    <p>Commercialis\u00e9 aux Etats-Unis par le partenaire am\u00e9ricain Harrow et en Chine par Ocumension Therapeutics<\/p>\n<p>Partenariats aussi en Asie du Sud-Est et au Moyen Orient<\/p>\n\n                                                <\/div>\n                                                                                    <\/h2>\n\n                                    \n                                <\/header>\n\n                                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                                                                        \n                                        <h3 class=\"[ c-portfolio__milestone-title ] [ u-gap-top-minus-2 sm:u-gap-top-base u-text-minus-2 u-weight-bold ]\">\n                                            Etapes attendues : \n                                        <\/h3>\n\n                                    \n                                                                        \n                                        <ul>\n                                                                                            <li>Revenus r\u00e9currents<\/li>\n                                                                                    <\/ul>\n\n                                    \n                                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                                    <div class=\"u-color-grey-2\">\n\n                                        <p>ZERVIATE\u00ae est un collyre innovant et de formulation brevet\u00e9e de c\u00e9tirizine approuv\u00e9 aux Etats-Unis pour le traitement du prurit oculaire associ\u00e9 aux conjonctivites allergiques.<\/p>\n<p>ZERVIATE est commercialis\u00e9 aux \u00c9tats-Unis par le partenaire am\u00e9ricain exclusif Harrow, Inc. et en Chine par Ocumension Therapeutics.<\/p>\n<p>La formulation de ZERVIATE est prot\u00e9g\u00e9e par des brevets d\u00e9livr\u00e9s aux Etats-Unis jusqu\u2019en 2030 et 2032, et jusqu\u2019en 2030 en Europe, au Japon et au Canada.<\/p>\n<p>Plus d\u2019informations sur ZERVIATE aux Etats-Unis sur le site de notre partenaire <a href=\"https:\/\/www.zerviate.com\/\">https:\/\/www.zerviate.com<\/a><\/p>\n\n\n                                    <\/div>\n\n                                <\/div>\n\n                            <\/div>\n\n                        <\/div>\n                        \n                    <\/article>\n                    \n                \n            <\/div>\n\n        <\/div>\n    \n    \n<\/section>\n\n\n<section class=\"[ c-full-video ] [ u-color-white u-bg-blue-7  u-bg-blue-7 u-color-white ]\">\n\n    <div class=\"c-block-anchor\" id=\"block_538c3721a8f02c6a5021b7539b960cb2\"><\/div>\n\n    \n        <div class=\"[ c-video-content u-bg-cover ]\" style=\"background-image: url('https:\/\/i.vimeocdn.com\/video\/1181422138-98c23ca8a59b5a5f9168dd62ea9aca3a9c06fa0e8c78e80491abd75f6d6306f2-d_640?region=us');\">\n\n            <lite-vimeo videoid=\"571214584\"><\/lite-vimeo>\n\n            \n                <span class=\"[ c-full-video__title ] [ u-text-plus-1 sm:u-text-plus-2 md:u-text-plus-3 lg:u-text-plus-4 u-weight-light ]\">Watch how our science works<\/span>\n\n            \n        <\/div>\n\n    \n\n<\/section>\n\n\n<section class=\"[ c-centered-column c-wrapper ] [ u-vertical-padding ] [   ]\">\n\n    <div class=\"c-block-anchor\" id=\"nitric-oxide-donation\"><\/div>\n\n    <div class=\"c-container\" data-variant=\"wide-column\">\n\n                    \n            <h2 class=\"[ c-centered-column__title ] [ u-text-plus-4 md:u-text-plus-5 lg:u-text-plus-6 u-weight-light ]\">\n                Nitric oxide donation\n            <\/h2>\n\n            \n    <\/div>\n\n    <div class=\"[ c-container ] [ c-text-content ]\" data-variant=\"narrow-column\">\n\n                    <h3 class=\"u-caps-heading\">\n                The Nicox expertise\n            <\/h3>\n        \n                    <div class=\"u-gap-top-base\">\n                <p>We have developed a leading position in the therapeutic application of nitric oxide (NO)-donating compounds in ophthalmology using our proprietary expertise in generating novel, patentable molecules that release NO, creating a significant patent portfolio.<\/p>\n<p>Our NO-donating research platform produced NO-donating compounds targeting glaucoma, including VYZULTA<sup>\u00ae<\/sup>, our first FDA-approved product, commercialized in the United States and other countries by our exclusive global licensee, Bausch + Lomb, and NCX 470, currently in Phase 3 clinical development.<\/p>\n\n            <\/div>\n        \n        <button class=\"[ c-icon-link ] [ u-gap-top-base ]\" data-variant=\"medium\" data-disclosure-toggle=\"expertise-nitric-oxide-donation\" data-open-details>\n\n            <span class=\"c-icon-link__text\">\n                Read more\n            <\/span>\n\n            <span class=\"c-icon c-icon-link__icon\">\n                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n            <\/span>\n\n        <\/button>\n\n        <div class=\"[ c-wrapper c-detail c-expertise__detail ]\" data-disclosure-target=\"expertise-nitric-oxide-donation\">\n\n            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"expertise-nitric-oxide-donation\" data-close-details><\/button>\n\n                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"expertise-nitric-oxide-donation\" data-close-details>\n\n                        <span class=\"c-icon-link__text\">\n                            Fermer\n                        <\/span>\n\n                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                        <\/span>\n\n                    <\/button>\n\n                    <div>\n\n                        \n                            <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold ]\">\n                                Nitric oxide donation\n                            <\/h2>\n\n                        \n                        \n                            <span class=\"[ c-detail__subtitle ] [ u-color-white u-text-plus-1 sm:u-text-plus-2 u-weight-bold ]\">\n                                The Nicox expertise\n                            <\/span>\n\n                        \n                    <\/div>\n\n                <\/header>\n\n                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                    <div class=\"u-color-grey-2\">\n\n                        <p>We have focused our research efforts on ocular disorders in which NO is believed to play a role, including lowering intraocular pressure (IOP) in glaucoma or in retinal health.<\/p>\n<p>NO is a well-known, small, naturally occurring signaling molecule known to stimulate an intracellular enzyme, soluble guanylate cyclase (sGC), which converts guanosine triphosphate to the second messenger, cyclic guanosine monophosphate (cGMP). NO\/sGC signaling pathway plays a key role in the regulation of IOP homeostasis and ocular blood flow. The NO stimulated increase in cGMP in the trabecular meshwork leads to the reduction of intracellular calcium, relaxation of the trabecular meshwork and, consequently, an increase in the outflow of the aqueous humor from the anterior segment of the eye through the primary or conventional outflow pathway. All of the foregoing events are thought to lead to lowering of IOP and enhance ocular perfusion. The effect of NO on IOP may be further increased and\/or prolonged by phosphodiasterase type-5 (PDE5) inhibitors, which inhibit the degradation of cGMP.<\/p>\n<p>We are applying key learnings from our research activities to NO-donating moieties attached to other non-PGA therapeutic classes of compounds with the goal of enhancing the NO-mediated effects. This novel class of molecules has the potential for development in retinal conditions and a candidate in this series is under preclinical development for retinopathies and other back-of-eye diseases.<\/p>\n\n\n                    <\/div>\n\n                <\/div>\n\n            <\/div>\n\n        <\/div>\n\n    <\/div>\n\n<\/section>\n\n\n<section class=\"[ c-publications c-wrapper ] [  ]\">\n\n    <div class=\"c-block-anchor\" id=\"publications\"><\/div>\n\n    <div class=\"c-container\">\n\n        <hr>\n\n                \n            <h2 class=\"c-publications__title ] [ u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                Publications\n            <\/h2>\n        \n        \n        \n            <div class=\"[ c-accordion ] [ u-gap-top-plus-4 ]\">\n\n                \n                    <button class=\"[ c-accordion__title ] [ u-caps u-color-blue-55 u-text-base sm:u-text-plus-1 u-weight-light ]\" data-disclosure-toggle=\"publication-ncx-470\">\n\n                        NCX 470\n\n                        <span class=\"[ c-accordion__label ] [ u-text-minus-2 ]\">\n                            <span class=\"c-icon c-accordion__icon\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 9.4 6.1\">\n  <path d=\"M4.7 6.1L0 1.4 1.4 0l3.3 3.3L8 0l1.4 1.4z\" data-name=\"Path 36\"\/>\n<\/svg>\n                            <\/span>\n                        <\/span>\n\n                    <\/button>\n\n                \n                <div class=\"[ c-accordion__panel ] [ u-links-plain ]\" data-disclosure-target=\"publication-ncx-470\">\n\n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Baseline Intraocular Pressures\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/AGS-2024-_-Fechtner-poster.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated Versus Treatment-Na\u00efve Patients\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/AGS-2024-_-Mansberger-poster.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                                    \n                <\/div>\n            \n            <\/div>\n        \n        \n            <div class=\"[ c-accordion ] [ u-gap-top-plus-4 ]\">\n\n                \n                    <button class=\"[ c-accordion__title ] [ u-caps u-color-blue-55 u-text-base sm:u-text-plus-1 u-weight-light ]\" data-disclosure-toggle=\"publication-vyzulta\">\n\n                        VYZULTA\n\n                        <span class=\"[ c-accordion__label ] [ u-text-minus-2 ]\">\n                            <span class=\"c-icon c-accordion__icon\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 9.4 6.1\">\n  <path d=\"M4.7 6.1L0 1.4 1.4 0l3.3 3.3L8 0l1.4 1.4z\" data-name=\"Path 36\"\/>\n<\/svg>\n                            <\/span>\n                        <\/span>\n\n                    <\/button>\n\n                \n                <div class=\"[ c-accordion__panel ] [ u-links-plain ]\" data-disclosure-target=\"publication-vyzulta\">\n\n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                                    \n                <\/div>\n            \n            <\/div>\n        \n        \n            <div class=\"[ c-accordion ] [ u-gap-top-plus-4 ]\">\n\n                \n                    <button class=\"[ c-accordion__title ] [ u-caps u-color-blue-55 u-text-base sm:u-text-plus-1 u-weight-light ]\" data-disclosure-toggle=\"publication-new-class-of-no-mediated-intraocular-pressure-lowering-agents\">\n\n                        New class of NO-mediated intraocular pressure lowering agents\n\n                        <span class=\"[ c-accordion__label ] [ u-text-minus-2 ]\">\n                            <span class=\"c-icon c-accordion__icon\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 9.4 6.1\">\n  <path d=\"M4.7 6.1L0 1.4 1.4 0l3.3 3.3L8 0l1.4 1.4z\" data-name=\"Path 36\"\/>\n<\/svg>\n                            <\/span>\n                        <\/span>\n\n                    <\/button>\n\n                \n                <div class=\"[ c-accordion__panel ] [ u-links-plain ]\" data-disclosure-target=\"publication-new-class-of-no-mediated-intraocular-pressure-lowering-agents\">\n\n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                                    \n                <\/div>\n            \n            <\/div>\n        \n        \n            <div class=\"[ c-accordion ] [ u-gap-top-plus-4 ]\">\n\n                \n                    <button class=\"[ c-accordion__title ] [ u-caps u-color-blue-55 u-text-base sm:u-text-plus-1 u-weight-light ]\" data-disclosure-toggle=\"publication-no-donors\">\n\n                        NO donors\n\n                        <span class=\"[ c-accordion__label ] [ u-text-minus-2 ]\">\n                            <span class=\"c-icon c-accordion__icon\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 9.4 6.1\">\n  <path d=\"M4.7 6.1L0 1.4 1.4 0l3.3 3.3L8 0l1.4 1.4z\" data-name=\"Path 36\"\/>\n<\/svg>\n                            <\/span>\n                        <\/span>\n\n                    <\/button>\n\n                \n                <div class=\"[ c-accordion__panel ] [ u-links-plain ]\" data-disclosure-target=\"publication-no-donors\">\n\n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                    \n                        \n                        \n                        \n                        \n                                    \n                <\/div>\n            \n            <\/div>\n        \n        \n    <\/div>\n\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-10362","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pipeline, Markets and Science - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/pipeline-markets-and-science\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pipeline, Markets and Science - Nicox\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/pipeline-markets-and-science\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-04T06:26:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/pipeline-markets-and-science\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/pipeline-markets-and-science\\\/\",\"name\":\"Pipeline, Markets and Science - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2021-07-07T16:50:34+00:00\",\"dateModified\":\"2025-09-04T06:26:05+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/pipeline-markets-and-science\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pipeline, Markets and Science - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/pipeline-markets-and-science\/","og_locale":"fr_FR","og_type":"article","og_title":"Pipeline, Markets and Science - Nicox","og_url":"https:\/\/www.nicox.com\/fr\/pipeline-markets-and-science\/","og_site_name":"Nicox","article_modified_time":"2025-09-04T06:26:05+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/pipeline-markets-and-science\/","url":"https:\/\/www.nicox.com\/fr\/pipeline-markets-and-science\/","name":"Pipeline, Markets and Science - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2021-07-07T16:50:34+00:00","dateModified":"2025-09-04T06:26:05+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/pipeline-markets-and-science\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/pages\/10362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=10362"}],"version-history":[{"count":8,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/pages\/10362\/revisions"}],"predecessor-version":[{"id":18153,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/pages\/10362\/revisions\/18153"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=10362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}